'Brand Name or Equal to Brightfield': FDA Seeks AI Reading of Cannabis Posts on TikTok and Reddit

Years before the federal government put it in a procurement document, Bethany Gomez had a line she liked to use about her company's specialty. "Social media is really the world's largest focus group," the co-founder and managing director of Brightfield Group told an industry publication in 2022. "There is so much data created by social media." Brightfield, founded in Chicago in 2015 because cannabis had no reliable market data, built a business on "social listening": pulling public posts from Instagram, Reddit and other platforms, running machine learning over them, and selling the patterns to consumer brands. Government agencies, Gomez noted at the time, were already among the users of Brightfield's data. (S1)

This month, the biggest one put that relationship in writing. The Food and Drug Administration issued a request for quotes for external data and analytics services on cannabis, CBD and "emerging products," and it did not describe the capability generically. The posting specifies "brand name or equal to Brightfield Group online data subscription and analytic services." Quotes were due Monday. The contract would run from September 30, 2026 through September 29, 2027. (S2, S3)

What the FDA wants is broad. The social-media component would monitor cannabis and hemp conversations on TikTok, Instagram and Reddit and "capture data on products, ingredients, claims, consumer conditions, sentiments, and other attributes," filterable "by age-group, sex, persona, and other attributes... using trained artificial intelligence (AI) modeling, with click-through to verbatim conversation postings." The stated purpose: to "address knowledge gaps on cannabis, cannabidiol (CBD), and emerging products and help inform work on policy and regulation, education and outreach, and compliance activities." (S2)

The surveys go further than the scrolling. The contractor would field a "US Cannabis Consumer Survey" of dispensary shoppers covering "symptoms and paths to purchase, as well as product preferences, desired effects, medical conditions, occasions, frequency and history of use, average purchases, and preferred dosages." A general-population survey would take in cannabis alongside kratom, psilocybin and other products marketed with functional claims. A third would examine women's cannabis purchasing "by life-stage," which the posting defines as "fertility/prime, perimenopause, and postmenopause." For CBD, the agency wants market sizing: top brands, product types, claimed content, "including those that are state regulated." (S2)

The scope maps closely onto what Brightfield already sells. The company's trackers measure conversation volume around CBD and hemp-derived cannabinoids and sort speakers into consumer profiles; its evergi platform, launched in 2021, watches cannabis and CBD alongside psychedelics, nootropics and other wellness products in the general population, nearly the same basket as the FDA's proposed general-population survey. Gomez, who worked at the research firm Euromonitor International before co-founding Brightfield in 2015, has said the company exists because "there were no good data options for companies to make strategic or investment decisions." The federal government has now reached the same conclusion about itself. (S1)

None of this arrived from nowhere. In October 2021 the FDA published a Cannabis-Derived Products Data Acceleration Plan, arguing the agency needed "robust information" about safety signals and "general patterns of product use and emerging trends... in close to real time," and that novel data sources could supply it. In 2022 it floated a sources-sought notice for small businesses that could mine social media, e-commerce sites and even the dark web for cannabis-product intelligence, explicitly naming machine learning and natural-language processing. The 2018 Farm Bill had legalized hemp and set off a market the agency admitted it could not see clearly. The new request is that four-year-old idea with a budget line and a deadline. (S4, S5)

It also has an instruction behind it. Executive Order 14370, signed December 18, 2025, directed the Attorney General to finish marijuana rescheduling "in the most expeditious manner" and, in the same breath, told the Secretary of Health and Human Services, the FDA Commissioner and the heads of CMS and NIH to "develop research methods and models utilizing real-world evidence" for cannabinoid products. A social-listening contract with a consumer-survey program attached is about as literal a translation of "real-world evidence" into procurement as an agency can produce. The order also tasked the White House with negotiating a new statutory framework for hemp products, whose federal ban, under last year's appropriations deal, is still scheduled to land this fall. (S6)

The regulatory posture underneath is unchanged and awkward. The FDA has never approved a marketing application for cannabis for any condition; it has approved exactly one cannabis-derived prescription drug and three cannabis-related ones. It has never allowed CBD into dietary supplements, issuing responses to citizen petitions on the question in January 2023 and sending warning letters to companies selling CBD and delta-8 products with therapeutic claims. The agency, in other words, is commissioning granular consumer intelligence on a market it has declined to regulate into legitimacy, at the very moment rescheduling and hemp legislation may force it to. (S7)

The CBD assignment carries its own irony. The posting asks for data on non-intoxicating cannabis products "including size; top brands; product types, forms, claimed content; and other pertinent market attributes... including those that are state regulated." Those state-regulated products exist in a space the FDA itself created by inaction: the agency spent five years studying whether to allow CBD in foods and supplements, and has held since 2023 that the question belongs to Congress. The brands the contractor will rank are, in the FDA's own framing, mostly unlawful to market with health claims. The agency is asking for a map of a gray market it declined to make legal. (S2, S7)

That distinction is where the commentary has landed. High Times, in an analysis of the request, wrote that "the FDA is sneaking into your DMs" would be the creepier headline, "but that is not what the available documents show." What the documents do show, the magazine wrote, is that "a federal agency wants a much more granular view of how cannabis consumers behave and talk online," not one employee "doomscrolling r/trees" but "an industrial-scale system" for converting what consumers post voluntarily into regulatory data. "Whether that sounds reassuring or unsettling," the analysis concluded, "probably depends on which part of that sentence you focus on." (S3)

There is a case for the project that consumer advocates themselves have made for years: the federal government writes cannabis policy while knowing remarkably little about actual use. The executive order's own recitals lean on survey fragments, one in five adults reporting CBD use in the past year, 20% of veterans in one survey reporting reduced opioid use, barely half of older consumers telling their doctors at all. An agency that knew what dispensary shoppers actually buy, at what doses, for what symptoms, would write better rules than one that does not. The unease is the mirror image: the same dataset that informs education campaigns also informs "compliance activities," which is the posting's own word, and the industry's memory of FDA compliance activity is a stack of warning letters. (S6, S2, S7)

“Social media is really the world's largest focus group. There is so much data created by social media.”

— Bethany Gomez, Co-founder and Managing Director, Brightfield Group

For Brightfield, being named in a federal solicitation as the benchmark, "brand name or equal," is the kind of endorsement market-research firms do not get to buy. The company has spent a decade building consumer panels and social-listening trackers across CBD, hemp-derived cannabinoids and state cannabis markets, work Gomez once described as hard precisely because the industry is "a living, breathing thing" fragmented across state lines. Competitors can still bid; the phrase invites equivalents. But the agency has told the market whose product it had in mind. (S2, S1)

1. Quotes were due to the FDA the week of Aug. 24; an award would put the contract in force Sept. 30, 2026.
2. The DEA's separate rescheduling hearing wrapped final briefs the week of Aug. 17, with the administrative law judge's recommendation the next step.
3. The federal hemp-product restrictions enacted in last year's appropriations law remain scheduled to take effect this fall unless Congress revises them, a change Executive Order 14370 instructed the White House to pursue.
4. The contract's first-year deliverables, if awarded, would land inside the same 12 months in which FDA may finally be handed formal authority over hemp-derived cannabinoids.

Behind the procurement sits a genuine evidentiary hole that the government has now documented twice at the highest level. The 2023 HHS review that grounded the rescheduling recommendation found credible scientific support for marijuana in treating pain, chemotherapy-induced nausea and anorexia related to medical conditions, based partly on the fact that more than 30,000 licensed practitioners across 43 jurisdictions were already recommending it to over 6 million registered patients. That is an enormous uncontrolled experiment running in public, and the December order's complaint is that federal science has mostly declined to observe it. A year of social listening and dispensary surveys will not settle efficacy. It would, for the first time, tell the FDA what the experiment actually looks like. (S6)

The strangest thing about the request may be how unremarkable it will soon look. Consumer-products companies have bought exactly this intelligence from Brightfield and its competitors for a decade; the FDA is late to a market that formed in the absence of its guidance. Gomez's focus group has been running the whole time, tens of millions of Americans narrating their consumption in public, one post at a time. The only new participant is the regulator, finally pulling up a chair to listen. (S1, S2)

Keep Reading

Tech & E-Commerce

Australia’s Cannabis Platforms Face a Test of Who Controls the Prescription

The TGA’s 2026-27 plan puts unapproved medicines and closed-loop supply chains under review. Doctors, pharmacists and industry groups disagree over how to preserve convenient access while keeping clinical decisions independent of sales.

By Cannabis Inc, Editorial Staff·7 min read

Tech & E-Commerce

Weedmaps Was Worth $1.5 Billion. It Just Quit Nasdaq Worth $45 Million.

Justin Hartfield's gray-market dispensary directory grew into the SPAC era's cannabis darling, then the 'cannabis winter' and a regulatory reckoning gutted it. On April 24, a smaller, profitable WM Technology delisted to the OTC markets, with its CEO calling the retreat a path to victory.

By Cannabis Inc, Editorial Staff·8 min read